Floatz logo

PERFLUTREN

Pulmonary Dysplasia

Thunder Bay Regional Health Research InstituteSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pulmonary Dysplasia cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
National Center for Research Resources (NCRR)
Phase 3B
Solu-Cortef
National Center for Research Resources (NCRR)
Phase 2B
XENON
Thunder Bay Regional Health Research Institute
Early Phase 1C
Helium
Thunder Bay Regional Health Research Institute
Early Phase 1C
Sonovue
Thunder Bay Regional Health Research Institute
Early Phase 1C
RED BLOOD CELLS
Hospital Clinic of Barcelona
N/AD
Cord Blood Red Blood Cells
Hospital Clinic of Barcelona
N/AD

Same molecule, other indications

PERFLUTREN is also rated in:

Recurrent Renal Cell CarcinomaDormant
B
Indicative ·
60 / 100
View asset →
asthmaDormant
B
Indicative ·
60 / 100
View asset →
Kidney CancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →